Compare Cassava Sciences Inc (FLNA) vs Corning Incorporated (GLW) Price & Performance

Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.

The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.

Corning (GLW) trades at $187.68, up 2.36% today, with a neutral technical signal and bearish moving averages. Recent earnings beats and strong 2025 results, including $15.63B revenue and $1.60B net income, highlight fundamental strength. The stock has retreated from its June 2026 peak of $271.38, with analyst consensus pointing to a $210.10 price target. Key support lies at $185, with resistance at $191.

The outlook remains positive due to AI-driven optical communication demand and partnerships with NVIDIA and Amazon. Risks include market volatility and competitive pressures, but institutional sentiment is bullish with 54% buy ratings. Upside potential exists if the company maintains its earnings momentum and capitalizes on infrastructure spending trends.